Telik, Inc.
3165 Porter Drive
Palo Alto
California
94304
United States
Tel: 650-845-7700
Fax: 650-845-7800
Website: http://www.telik.com/
Email: inquiry@telik.com
145 articles about Telik, Inc.
-
Telix Pharmaceuticals Appointed Dr. Bernard Lambert as President of Telix Pharmaceuticals (US) Inc.
12/4/2017
Dr. Lambert was previously Vice President, CMC and Radiopharmaceutical Development at Zevacor Molecular and IBA Molecular.
-
MabVax Therapeutics, Inc. Receives Stockholder Approval For Name Change And Reverse Stock Split Resulting From Merger With Telik, Inc.
9/9/2014
-
Telik, Inc. Reports Progress Toward Multiple Early Stage Milestones In The Development Of A Novel Antibody-Based Therapeutic Agent For Gastrointestinal Cancers
8/28/2014
-
Telik, Inc. Receives $1.5 Million National Cancer Institute Contract To Develop Novel Antibody-Based PET Imaging Agent For Pancreatic Cancer
8/25/2014
-
San Diego's Telik, Inc. Appoints New Board Members To Oversee Reinvigorated Cancer Pipeline
8/12/2014
-
Telik, Inc. Announces New Board Of Director Members To Oversee Reinvigorated Cancer Therapy Pipeline Resulting From The Recent Merger With MabVax Therapeutics, Inc.
8/11/2014
-
Telik, Inc. Announces Plans For Special Meeting Of Stockholders And Transition To MabVax Therapeutics, Inc.
8/4/2014
-
Mintz Levin Represents San Diego-Based MabVax Therapeutics, Inc. In IPO Through Merger With Telik, Inc.
7/11/2014
-
MabVax Therapeutics, Inc. And Telik, Inc. Announce Closing Of Merger
7/9/2014
-
Telik, Inc. Announces First Quarter 2014 Financial Results
5/16/2014
-
Telik, Inc. And MabVax Therapeutics, Inc. Announce Definitive Merger Agreement
5/13/2014
-
Telik, Inc. Announces Third Quarter 2013 Financial Results
11/13/2013
-
Telik, Inc. Announces Second Quarter 2013 Financial Results
8/12/2013
-
Telik, Inc. Announces First Quarter 2013 Financial Results
5/13/2013
-
Telik, Inc. Announces Fourth Quarter and 2012 Year End Financial Results and 2013 Financial Guidance
3/18/2013
-
Telik, Inc. Announces Preliminary Agreement on Design of Phase 3 Registration Trial of Telintra® in Low to Intermediate-1 Risk Myelodysplastic Syndrome
1/23/2013
-
Telik, Inc. Announces Orphan Designation of Telintra® for Treatment of Myelodysplastic Syndrome
1/14/2013
-
Telik, Inc. Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology
12/13/2012
-
Telik, Inc. Announces Third Quarter 2012 Financial Results
11/12/2012
-
Telik, Inc. Announces Second Quarter 2012 Financial Results
8/13/2012